Joerg Breitkreutz

Prof. Dr. Joerg Breitkreutz

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2011 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
EHEva Maria Hoffmann
Eva Maria Hoffmann
ABArmin Breitenbach
Armin Breitenbach
JBJoerg Breitkreutz
Joerg Breitkreutz
DPDipl Pharm
Dipl Pharm
PDPh D
Ph D
(2011). Advances in orodispersible films for drug delivery. Expert Opinion on Drug Delivery: Vol. 8, No. 3, pp. 299-316. doi: 10.1517/17425247.2011.553217

21 December 2006 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
JBJoerg Breitkreutz
Joerg Breitkreutz
JBJoachim Boos
Joachim Boos
(2007). Paediatric and geriatric drug delivery. Expert Opinion on Drug Delivery: Vol. 4, No. 1, pp. 37-45.

1 June 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
JWJennifer Walsh
Jennifer Walsh
ACAnne Cram
Anne Cram
KWKatharina Woertz
Katharina Woertz
JBJoerg Breitkreutz
Joerg Breitkreutz
GWGesine Winzenburg
Gesine Winzenburg
Catherine TuleuCatherine Tuleu
Catherine Tuleu
The development of paediatric medicines can be challenging since this is a diverse patient population with specific needs. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Acceptable palatability of oral paediatric medicinal products is of great importance to facilitate patient adherence. This has been recognised by regulatory authorities and so is becoming a key aspect of paediatric pharmaceutical development studies. Many active pharmaceutical ingredients (APIs) have aversive taste characteristics and so it is necessary to utilise taste masking techniques to improve the palatability of paediatric oral formulations. The aim of this review is to provide an overview of different approaches to taste masking APIs in paediatric oral dosage forms, with a focus on the tolerability of excipients used. In addition, where possible, the provision of examples of some marketed products is made.

1 July 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MSMarta Slavkova
Marta Slavkova
JBJoerg Breitkreutz
Joerg Breitkreutz

1 September 2011 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
KWKatharina Woertz
Katharina Woertz
CTCorinna Tissen
Corinna Tissen
PKPeter Kleinebudde
Peter Kleinebudde
JBJoerg Breitkreutz
Joerg Breitkreutz

1 July 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SSS. Stegemann
S. Stegemann
MGM. Gosch
M. Gosch
JBJoerg Breitkreutz
Joerg Breitkreutz